Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics

Psychiatry and Clinical Neurosciences

Volumn 56, Issue 4, 2002, Pages 469-474

  Woo, Sung Il ^a   Kim, Jae Won ^b   Rha, Eugene ^b   Han, Sun Ho ^a   Hahn, Kyu Hee ^c   Park, Chul Soo ^c   Sohn, Jin Wook ^c  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Research Institute of Life Science   (South Korea)

^c Gyeongsang National University School of Medicine   (South Korea)

Author keywords

Dopamine D3 receptor; Korean; MscI; Polymorphism; Tardive dyskinesia

Indexed keywords

DOPAMINE 3 RECEPTOR; GLYCINE; NEUROLEPTIC AGENT; SERINE;

ADULT; ARTICLE; DNA POLYMORPHISM; FEMALE; FISHER EXACT TEST; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOTE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; SCHIZOPHRENIA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENOTYPE; HUMANS; KOREA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA;

EID: 0036342556     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.2002.01038.x     Document Type: Article

References (40)

1. Medication-induced movement disorders
2. Gender differences in tardive dyskinesia: A critical review of the literature
3. Tardive dyskinesia
4. Tardive dyskinesia: Pathophysiology and animal models
5. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
6. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects
7. Biochemical anatomy: Insights into cell biology and pharmacology of the dopamine and serotonin systems in the brain
8. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis
9. The effects of clozapine on tardive dyskinesia
10. Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia
11. A mechanism underlying neuroleptic-induced oral dyskinesia in rats
12. A sub-population of dopamine D1 receptors mediate repetitive jaw movements in rats
13. Tardive dyskinesia and ethnicity: Review of the literature
14. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
15. Non-functional CYP2D6 alleles and risk factors for neuroleptic-induced movement disorders in schizophrenic patients
16. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
17. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics
18. No association of CYP2D6*4 and CYP2D6*10 polymorphisms with tardive dyskinesia in Korean schizophrenics
19. Association of TaqI a polymorphism of dopamine D-2 receptor gene and tardive dyskinesia in schizophrenia
20. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia
21. 3 receptor gene with tardive dyskinesia in schizophrenia
22. 3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
23. Dopamine D3 receptor variant and tardive dyskinesia
24. Search for a susceptibility locus to tardive dyskinesia
25. Research diagnoses for tardive dyskinesia
26. 3 receptor as a useful polymorphism for investigating psychiatric disorders
27. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
28. 3 dopamine receptor gene
29. Evidance for an association between the dopamine D3 receptor gene (DRD3) and schizophrenia
30. Association study of dopamine D3 receptor gene and schizophrenia
31. 3 receptor gene
32. A study of the association between schizophrenia and the dopamine D3 receptor gene
33. The D3 dopamine receptor: Neurobiology and potential clinical relevance
34. Behavioral effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other 'D-2-like' agonists
35. 3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release
36. 3 receptors
37. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice
38. Proposed schizophrenia-related gene polymorphism: Expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki forest virus system
39. Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa